NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AML-ETO9a acute myeloid leukemia. Replacing α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogene-driven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies.

[1]  M. Smyth,et al.  Role of γδ T Cells in α-Galactosylceramide–Mediated Immunity , 2012, The Journal of Immunology.

[2]  L. Metelitsa.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. , 2011, Clinical immunology.

[3]  J. Berzofsky,et al.  Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. , 2011, The Journal of clinical investigation.

[4]  H. Kohrt,et al.  A Cpg-loaded Tumor Cell Vaccine Induces Antitumor Cd4 Ϩ T Cells That Are Effective in Adoptive Therapy for Large and Established Tumors Results Cpg Loading Is Required for Effective Vaccination in Tlr9-competent Hosts , 2022 .

[5]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[6]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[7]  I. Frazer,et al.  Secretion of IFN-γ but Not IL-17 by CD1d-Restricted NKT Cells Enhances Rejection of Skin Grafts Expressing Epithelial Cell-Derived Antigen , 2010, The Journal of Immunology.

[8]  T. Wirth,et al.  Advances in the understanding of MYC‐induced lymphomagenesis , 2010, British journal of haematology.

[9]  C. Bogdan,et al.  IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo , 2010, European journal of immunology.

[10]  D. Godfrey,et al.  Raising the NKT cell family , 2010, Nature Immunology.

[11]  J. Berzofsky,et al.  The contrasting roles of NKT cells in tumor immunity. , 2009, Current molecular medicine.

[12]  G. Renukaradhya,et al.  Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. , 2008, Blood.

[13]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[14]  J. Berzofsky,et al.  The role of NKT cells in tumor immunity. , 2008, Advances in cancer research.

[15]  R. Steinman,et al.  Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells , 2007, The Journal of experimental medicine.

[16]  L. Kwak,et al.  An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. , 2007, Blood.

[17]  P. Moss,et al.  Immunodeficiency and immunotherapy in multiple myeloma , 2007, British journal of haematology.

[18]  Mark J. Smyth,et al.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma , 2007, Proceedings of the National Academy of Sciences.

[19]  M. Taniguchi,et al.  Tumor Cells Loaded with α-Galactosylceramide Induce Innate NKT and NK Cell-Dependent Resistance to Tumor Implantation in Mice1 , 2007, The Journal of Immunology.

[20]  S. Mattarollo,et al.  Chemotherapy pretreatment sensitizes solid tumor‐derived cell lines to Vα24+ NKT cell‐mediated cytotoxicity , 2006, International journal of cancer.

[21]  R. Steinman,et al.  Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice , 2006 .

[22]  R. Steinman,et al.  Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Pellicci,et al.  Differential antitumor immunity mediated by NKT cell subsets in vivo , 2005, The Journal of experimental medicine.

[24]  Vrajesh V. Parekh,et al.  Glycolipid antigen induces long-term natural killer T cell anergy in mice. , 2005, The Journal of clinical investigation.

[25]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[26]  R. Steinman,et al.  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[27]  T. Iizasa,et al.  A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[28]  T. Iizasa,et al.  A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Stern,et al.  Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma , 2004, International journal of cancer.

[30]  S. Targan,et al.  TL1A Synergizes with IL-12 and IL-18 to Enhance IFN-γ Production in Human T Cells and NK Cells1 , 2004, The Journal of Immunology.

[31]  B. Hug,et al.  ETO interacting proteins , 2004, Oncogene.

[32]  V. Callea,et al.  CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytes , 2004, International journal of cancer.

[33]  T. Juji,et al.  Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity , 2004 .

[34]  T. Juji,et al.  Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. , 2004, Blood.

[35]  S. Targan,et al.  TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. , 2004, Journal of immunology.

[36]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[37]  A. Harris,et al.  NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 , 2003, The Journal of Immunology.

[38]  S. Nimer,et al.  Severe and selective deficiency of interferon‐γ‐producing invariant natural killer T cells in patients with myelodysplastic syndromes , 2003, British journal of haematology.

[39]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[40]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[41]  K. Weinberg,et al.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells , 2003, Leukemia.

[42]  G. Giaccone,et al.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[44]  R. Steinman,et al.  Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. , 2002, Nature immunology.

[45]  G. Giaccone,et al.  Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. , 2001, Journal of immunological methods.

[46]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[47]  I. Serizawa,et al.  Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. , 2001, Oncology research.

[48]  H. Fujiwara,et al.  Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[50]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[51]  M. Kronenberg,et al.  Immunization with α‐galactosylceramide polarizes CD1‐reactive NK T cells towards Th2 cytokine synthesis , 1999, European journal of immunology.

[52]  G. Trinchieri,et al.  IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. , 1999, Journal of immunology.

[53]  K. Guy,et al.  Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma. , 1986, British Journal of Cancer.

[54]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.